GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » Market Cap

XTL Biopharmaceuticals (XTAE:XTLB) Market Cap : ₪48.50 Mil (As of Jun. 05, 2024)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). XTL Biopharmaceuticals's share price for the quarter that ended in Mar. 2024 was ₪0.1. XTL Biopharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 544.91 Mil. Therefore, XTL Biopharmaceuticals's market cap for the quarter that ended in Mar. 2024 was ₪54.49 Mil.

XTL Biopharmaceuticals's quarterly market cap declined from Sep. 2023 (₪19.62 Mil) to Dec. 2023 (₪19.07 Mil) but then increased from Dec. 2023 (₪19.07 Mil) to Mar. 2024 (₪54.49 Mil).

XTL Biopharmaceuticals's annual market cap declined from Dec. 2021 (₪46.86 Mil) to Dec. 2022 (₪22.34 Mil) and declined from Dec. 2022 (₪22.34 Mil) to Dec. 2023 (₪19.07 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. XTL Biopharmaceuticals's Enterprise Value for Today is ₪39.78 Mil.


XTL Biopharmaceuticals Market Cap Historical Data

The historical data trend for XTL Biopharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals Market Cap Chart

XTL Biopharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.71 50.39 46.86 22.34 19.07

XTL Biopharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.89 20.71 19.62 19.07 54.49

Competitive Comparison of XTL Biopharmaceuticals's Market Cap

For the Biotechnology subindustry, XTL Biopharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XTL Biopharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Market Cap falls into.



XTL Biopharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

XTL Biopharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=₪0.035*544.906
=₪19.07

XTL Biopharmaceuticals's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=₪0.1*544.906
=₪54.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XTL Biopharmaceuticals  (XTAE:XTLB) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


XTL Biopharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


XTL Biopharmaceuticals (XTAE:XTLB) Business Description

Traded in Other Exchanges
Address
5 Badner Street, P.O.Box 8241, Ramat Gan, ISR, 5218102
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.